the treatmentof human viral andother infectious diseaseswatch now chris bardon md oncology impact fund discuss advances in cancer therapies bloomberg capital markets june 2016 related investment pharmasset companies mpm investment strategy mpm capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas . mpm is currently investing out of bv2014 its most recent venture fund . in 2015 mpm partnered with ubs to create the ubs oncology impact fund oif an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities . oif will support both basic cancer research as well as access to cancer care in developing countries . fund all bv2014 oncology impact fund investments current exited exit type all ipo m & a focus area all oncology other 23andme genetic reports for consumers to better appreciate their ancestry other current 28 7 small molecule therapeutics that modulate mirnas for treatment oncology current affymax inc. previously committed to developing novel drugs other exited aires clinical stage pharmaceutical company for pulmonary disorders other exited alinea pharmaceuticals inc. previously developed new treatments for metabolic conditions other exited allozyne inc. cancer and inflammatory disease therapeutic company oncology exited alnara orally delivered protein therapeutics to treat metabolic diseases other exited amphivena developing bispecific tandabs as a novel immunotherapy for hematological disorders oncology current anthera developing drugs for autoimmune diseases other exited aratana provides innovative therapies for companion animals other current archus orthopedics inc. previously developed implants to treat spine disorders other exited aryx therapeutics inc. previously focused on molecular design other exited astute medical improving the diagnosis of high risk medical conditions other current atopix therapeutics inc. developing novel treatments for asthma other current barrier therapeutics inc. specialized in dermatological creams and gels other exited biomarin innovative therapeutics to patients with serious unmet medical needs other exited blade therapeutics a discovery stage company focused on developing fibrosis treatments other current celladon developing a transformative therapy for heart failure other exited cellerant therapeutics inc. novel immunotherapies for oncology and blood related disorders oncology exited cerecor inc. developing innovative treatments for patients with cns disorders other exited ceregene inc. development and manufacturing of gene therapies other exited cerimon pharmaceuticals inc. developed and commercialized therapeutics for autoimmune diseases other exited chf solutions inc. manufactures medical devices for cardiac care . other exited chiasma developing oral drugs that were previously only available by injection other current clinical ink modernize clinical trials with esource & patient engagement tools other current conatus developing novel therapeutics for liver diseases other exited costim developing novel antibodies for cancer immunotherapy oncology exited cotherix inc. licensing of therapeutic products for cardiopulmonary diseases other exited digitx partners digital health investment partnership with astellas pharma other current dragonfly sciences inc. developing a new class of biosimilar products other exited ekr therapeutics provides acute care specialty products other exited elixir pharmaceuticals inc. develops novel pharmaceuticals for the treatment of metabolic diseases other exited endogastric solutions inc. endoluminal treatment of gastroesophageal reflux disease other exited endologix provides optimal solutions for endovascular aortic repair other current enteromedics inc. developer of vbloc neurometabolic therapy other current epizyme personalized therapeutics for patients with genetically defined cancer oncology current fortebio develops analytical systems that enable real time analysis of biomolecular interactions other exited harpoon therapeutics t cell redirection to deliver deep remissions oncology current helicos biosciences corporation genetic analysis for the research drug discovery and diagnostics other exited hypnion inc. development of novel therapeutics for cns disorders other exited iconic developing therapeutics for serious eye disorders other current idenix discovers and develops drugs for human viral diseases other exited idun pharmaceuticals inc. other exited innovative spinal technologies inc. developed treatments for spinal disorders other exited intercell ag modern prophylactic and therapeutic vaccines other exited intracel holdings corporation development and commercialization of cancer vaccines other exited iomx therapeutics ag targeting t cell evasion to treat cancer oncology current ipierian developing anti tau protein antibodies for neurodegenerative disease other exited kalobios pharmaceuticals inc. developing monoclonal antibodies for cancer care oncology exited macrogenics inc. oncology exited memory pharmaceuticals corp. developed drug candidates for the treatment of cns disorders other exited meritage pharma treatment for eosinophilic esophagitis eoe other exited mitobridge discovers and develops novel drugs that enhance mitochondrial function other current motus therapeutics inc. developing therapies for severe gastric mobility disorders other current neosil manufactures dermatology focused specialty pharmaceutical products other exited neovista inc. technologies for age related mucular degeneration other exited neuromed pharmaceuticals inc. produces pain therapies in the us other exited nevro developing a high frequency stimulation technology for chronic pain other exited oncorus developing a next generation immunotherapy platform to treat cancer oncology current oxagen limited a privately held biopharmaceutical company other current pacira acute care products including exparel for post surgical analgesia other exited peptimmune inc. designs peptides for therapeutics diagnostic kits & antibodies other exited pernix therapeutics inc. specialty primary care and generic medicines other exited pharmasset discovering and developing novel drugs to treat viral infections other exited pharmathene inc. acquire and develop products identified as urgent priorities other exited poniard pharmaceuticals inc. discovery development and commercialization of oncology products other exited portola pharmaceuticals inc. a biopharmaceutical company in the hematologic diseases fields other exited potenza therapeutics developing novel immunotherapies for the treatment of cancer oncology current proteon therapeutics developing a therapy to improve dialysis vascular access other current quatrx pharmaceuticals company treatment of moderate to severe dyspareunia fda approved in feb 2013 other exited radius health novel differentiated therapeutics for patients with osteoporosis other current raze therapeutics developing novel anti tumor agents through mitochondrial one carbon me oncology current rhythm developing peptide therapeutics for metabolic diseases other current rigel pharmaceuticals inc. small molecule development for inflammatory and autoimmune diseases oncology exited rinat neuroscience corp. develops treatment of diseases and disorders of the nervous system other exited sai drug discovery development and manufacturing services other exited selexys developing novel products to treat inflammatory diseases other current semma therapeutics developing cell based transformative therapies for diabetes patients other current sideris pharmaceuticals inc. development of new treatments for transfusion related iron overload other exited solasia developing commercializing oncology & oncology supportive care drugs oncology current somaxon pharmaceuticals inc. developed silenor for treatment of insomnia other exited surface logix inc. enhancing molecular functionality of pharmaceuticals other exited syndax developing and commercializing epigenetic therapies for cancer oncology current tcr2 inc. focused on engineering t cells for cancer therapy oncology current tercica inc. developed increlex for treatment of primary igf 1 deficiency other exited tetherex pharmaceuticals corporation operates in the healthcare industry focusing on biotechnology business other current theraclone sciences inc. screening technology for antibodies that ward off disease other exited tizona therapeutics inc. regulatory t cell suppression as a novel approach to fighting cancer oncology current trinetx platform to improve clinical research study design & recruitment other current true north therapeutics developing drugs which selectively inhibit the complement system other current vaccinogen inc. personalized vaccines to fight disease oncology other current valeritas marketing a disposable insulin delivery device other current vascular developing a novel antibody for diabetic nephropathy other current verastem inc. treating cancer by the targeted killing of cancer stem cells oncology exited verus pharmaceuticals inc. pediatric oriented specialty pharmaceutical company other exited xanodyne pharmaceuticals inc. integrated specialty pharmaceutical company other exited mpm team mpm s team is comprised of innovators entrepreneurs executives & investors role investment team medical & scientific advisors operations team location all cambridge san francisco patrick baeuerle patrick baeuerle ph.d. managing director cambridge read bio chris bardon christiana bardon m.d. managing director cambridge read bio vinay bhaskar vinay bhaskar ph.d. principal san francisco read bio laura brass laura brass ph.d. m.b.a. managing director cambridge read bio pablo cagnoni pablo j. cagnoni m.d. managing director read bio lauren cauley lauren cauley chief financial officer cambridge read bio george daley george daley m.d. ph.d. medical and scientific advisory board mpm & oif msab read bio thomas ebeling thomas ebeling medical and scientific advisors oif msab read bio luke evnin luke evnin ph.d. managing director san francisco read bio mitchell finer ph.d. mitchell finer ph.d. managing director cambridge read bio todd foley todd foley m.b.a. managing director cambridge read bio shinichiro fuse shinichiro fuse ph.d. principal cambridge read bio ansbert gadicke ansbert gadicke m.d. managing director cambridge read bio bard geesaman bard geesaman m.d. ph.d. managing director cambridge read bio william greene william greene m.d. venture partner san francisco read bio dan hicklin dan hicklin ph.d. managing director cambridge read bio robert horvitz h. robert horvitz ph.d. medical and scientific advisory board mpm & oif msab read bio sebastian meier ewert sebastian meier ewert ph.d. venture partner munich office read bio briggs morrison briggs morrison m.d. managing director cambridge read bio vas narasimhan vas narasimhan m.d. medical and scientific advisory board mpm msab read bio gary patou gary patou m.d. managing director san francisco read bio sarah reed sarah reed chief operating officer and general counsel cambridge read bio tony rosenberg tony rosenberg managing director cambridge read bio david ryan david p. ryan m.d. medical & scientific advisor oif msab read bio jim scopa jim scopa j.d. m.b.a. managing director san francisco read bio kazumi shiosaki kazumi shiosaki ph.d. managing director cambridge read bio greg sieczkiewicz greg sieczkiewicz j.d. ph.d. managing director & chief ip counsel cambridge read bio david stack david stack managing director cambridge read bio elizabeth stoner elizabeth stoner m.d. managing director cambridge read bio contact us info mpmcapital.com cambridge ma 450 kendall street cambridge ma 02142 phone 617 425 9200 see full map get directions san francisco ca 601 gateway boulevard suite 350 south san francisco ca 94080 phone 650 553 3300 see full map get directions print terms of use & disclosures 2016 september 22 2016 iomx therapeutics raises eur 40 million in series a round company establishes top tier investor base consisting of mpm capital sofinnova partners wellington partners and merck ventures september 19 2016 three mpm portfolio companies blade oncorus & rhythm named to fiercebiotech s 2016 fierce 15 list september 19 2016 radius announces publication of additional positive results from the phase 3 active trial of osteoporosis treatment september 14 2016 tizona therapeutics inc. appoints george golumbeski ph.d. to its board of directors august 16 2016 osteoporosis a disease with few treatment options may soon have one more read coverage in ny times and in press release august 15 2016 aratana secures third fda approval animal pain drug expected to be available to veterinarians in the fall of 2016 august 11 2016 harvard medical school appoints mpm medical and scientific advisory co chair george daley as new dean read more in the boston globe august 10 2016 iconic therapeutics announces final close of series c financing with additional 10 million investment august 1 2016 astellas and mpm capital launch digitx partners july 26 2016 mpm portfolio company blade therapeutics featured in the san francisco business times the july 19 article taking it personally cutting edge biotech snags 45 million discusses the latest round of funding for blade a company focused on finding therapies for fibrotic disease and mpm co founder luke evnin s personal commitment to the cause . july 21 2016 rhythm announces new england journal of medicine publication of setmelanotide phase 2 data for treatment of pomc deficiency obesity significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway july 20 2016 former bluebird bio blue cso takes the reins at oncorus ; startup launches with 57 million series a june 16 2016 mpm portfolio company semma therapeutics featured in boston globe boston area hospitals have teamed up with the harvard stem cell institute and semma therapeutics to make personalized cell based therapies and organize clinical trials . june 2 2016 chris bardon managing director for the oncology impact fund on bloomberg capital markets discussing advances in cancer therapies as the 2016 asco annual meeting gets underway may 27 2016 trinetx enters